Drugs / MHB088C
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07126665 | Sep 2025 → Aug 2029 expected | cancer | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07102004 | Jun 2023 → Jul 2026 overdue | — | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05652855 | Jan 2023 → Jan 2026 overdue | — | Minghui Pharmaceutical Pty Ltd | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06951243 | May 2025 → May 2026 overdue | neuroendocrine neoplasm | Beijing GoBroad Hospital | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06954246 | Jun 2025 → May 2027 expected | small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-08-25 | Qilu Pharmaceutical Co., Ltd. | Results 金融界丨齐鲁制药ADC创新药QLC5508临床研究成果入选2025年世界肺癌大会口头报告 qilu-pharma.com ↗
综上所述，QLC5508 在既往经治的 ES-SCLC 患者中显示出了显示出了优越的安全性、突出的抗肿瘤活性和长期的生存获益，2.0 mg/kg Q2W将作为后续进一步研究的推荐剂量。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-08-25 | Qilu Pharmaceutical Co., Ltd. | 金融界丨齐鲁制药ADC创新药QLC5508临床研究成果入选2025年世界肺癌大会口头报告 qilu-pharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHB088C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07102004 ↗ |
| Known as | MHB088C for Injection | “MHB088C for Injection, an antibody drug-conjugated molecule (ADC), is conjugated from a humanized monoclonal antibody targeting the B7-H3 molecule and a DNA topoisomerase I...” NCT06951243 ↗1“MHB088C for Injection, an antibody drug-conjugated molecule (ADC) MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W) or every 3 week (Q3W).” NCT07102004 ↗ |
| Action | Inhibit | “a DNA topoisomerase I inhibitor (TOP1i)” NCT06951243 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody” NCT06951243 ↗ |
| Route | Intravenous | “MHB088C will be administered intravenously” NCT05652855 ↗ |